IC
LENZ

Ikarian Capital’s LENZ Therapeutics LENZ Stock Holding History

Ikarian Capital’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-149,502
Closed -$4.32M – 226
2024
Q4 		$4.32M Sell
149,502
-55,011
-27% -$1.68M 0.59% 45
2024
Q3 		$4.86M Hold
204,513
– – 0.68% 42
2024
Q2 		$3.54M Buy
204,513
+119,513
+141% +$2.09M 0.62% 39
2024
Q1 		$1.9M Buy
+85,000
New +$1.77M 0.21% 91

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Ikarian Capital's LENZ Position: Q1 2025 in Review

Ikarian Capital sold out of LENZ Therapeutics (LENZ) in Q1 2025, closing a stake of 149,502 shares — an estimated $4.32M sold.

Ikarian Capital first reported a position in LENZ in Q1 2024 and held it in 4 quarters. The position peaked at $4.86M in Q3 2024. 105 funds tracked by Wall St. Rank hold LENZ as of Q1 2025.

  • Ikarian Capital reported no remaining LENZ Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 149,502 LENZ Therapeutics shares in Q1 2025, an estimated $4.32M.
  • Ikarian Capital first reported a position in LENZ Therapeutics in Q1 2024 and held it in 4 quarters.
  • Ikarian Capital's LENZ Therapeutics position peaked at $4.86M in Q3 2024.
  • 105 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.